Medivir AB Reports the First Patient Dosing of Fostrox + Lenvima in P-IIa Trial for the Treatment of Hepatocellular Carcinoma
Shots:
- The first patient has been dosed in the P-IIa dose-expansion portion of the P-Ib/IIa study evaluating the safety & efficacy of fostroxacitabine bralpamide (fostrox) + Lenvima (tyrosine kinase inhibitor) in ~30 patients with HCC at 14 clinics across the UK, Spain, and South Korea
- The preliminary results from the P-Ib study of fostrox + Lenvima were encouraging with a good safety and tolerability profile with no evidence of DLTs. In this combination arm, 30mg of fostrox was the RP2D
- Additionally, the P-Ib dose escalation part of the P-Ib/IIa study evaluating fostrox in combination with Keytruda (anti-PD-1 checkpoint inhibitor) is still ongoing
Ref: PRNewswire | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
